Just as recently as 2 years ago, in this column, we asked Colin S. Tan, MBBS, MMed (Ophth), FRCSEd (Ophth), and Louis W. Lim, MBBS, to summarize the optimal management of polypoidal choroidal vasculopathy (PCV).
Since that time, there have been several randomized clinical trials that have given us further insight on the management of this interesting condition.
PCV was once considered to be a variant of wet age-related macular degeneration (AMD). However, it is clear that the unique clinical features and high prevalence in pigmented individuals warrants a distinct approach to this disease that may or may not be different than for wet AMD. Fortunately, given recent Level 1 evidence, the community is beginning to reach consensus regarding a systematic approach to treating this condition.
In this column, Drs. Tan and Lim will provide an up-to-date summary of treatment options for PCV. They will be reviewing numerous clinical trials, including EVEREST, EVEREST II, FU-JISAN, PLANET, APOLLO, VAULT, and DRAGON. I am certain their insights and review of current treatment approaches will be educational for the retina community.
Polypoidal choroidal vasculopathy (PCV) is a variant of age-related macular degeneration (AMD) and commonly manifests with Type 1 choroidal neovascularization (CNV). 1 PCV is characterized by the presence of abnormal vascular channels that are located in the subretinal pigment epithelial (RPE) space, commonly known as a branching vascular network, and the presence of aneurysmal dilatations (the polyps or polypoidal lesions) (Figure 1 ). Although PCV occurs more frequently in some populations, especially Asians, 2, 3 it is a global disease and an important differential to consider in any patient presenting with features of neovascular AMD. 4 Although the treatment outcomes of PCV have been explored in various publications, [5] [6] [7] it is only in recent years that we have the results of randomized, controlled clinical trials to facilitate evidence-based management of this important disease. The past year has been particularly exciting, with the results of 1-year data from two large multicenter, randomized controlled trials on PCV being reported. In this paper, we will explore the results of some of the multicenter, randomized, controlled clinical trials on PCV and discuss how these influence the management paradigms of PCV. It is important, however, to remember that the results of different clinical trials cannot be compared directly, as the baseline characteristics of the study populations may be different. Important considerations include differences in baseline best-corrected visual acuity (BCVA), central subfield thickness, and CNV type diagnosed using fluorescein angiography. 
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DIAGNOSIS OF PCV
An important consideration in the management of any clinical condition is to first confirm that the diagnosis is made accurately. Currently, the gold standard for diagnosis of PCV is indocyanine green angiography (ICGA). [8] [9] [10] However, a hyperfluorescent lesion seen on ICGA may not necessarily be a polyp. Common misdiagnoses include typical neovascular AMD, retinal angiomatous proliferations, retinal microaneurysms, and artifacts arising from prominent choroidal vessels beneath a region of RPE atrophy. 4 Therefore, it is imperative to use established diagnostic criteria in evaluating whether a lesion is indeed PCV, such as the diagnostic criteria used and validated in the EVEREST and EVER-EST II studies. 9, 11, 12 
CLINICAL OUTCOME MEASURES IN PCV STUDIES
In most clinical trials of retinal diseases, important outcome measures include changes in BCVA 
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and retinal thickness measured using optical coherence tomography (OCT). For PCV studies, however, another important consideration is the rate of polyp closure or regression. Polyps that remain patent may bleed or leak, which results in worsening of VA. 13 In addition, some cases may develop large subretinal hemorrhages (Figure 2 ), often termed as "massive submacular hemorrhage," which may be associated with a poor prognosis and result in significant visual loss.
13-15
THE ROLE OF PHOTODYNAMIC THERAPY IN PCV MANAGEMENT
In earlier studies on PCV, it was reported that although treatment with anti-vascular endothelial growth factor (VEGF) agents resulted in improvements in VA and reduction in retinal thickness on OCT, the polyps often remained patent. 16, 17 As previously discussed, this may pose a risk of continued or recurrent hemorrhage and exudation. When photodynamic therapy (PDT) with verteporfin (Visudyne; Novartis International AG, Basel, Switzer- Practical Retina land) is used, either alone or together with anti-VEGF agents, the rate of polyp regression is much higher (Figure 3 ).
MULTICENTER CLINICAL TRIALS ON TREATMENT OF PCV WITH PDT
The results of several multicenter clinical trials of the treatment of PCV with PDT can be seen in Table 1 .
The first multicenter, randomized, controlled trial to address the efficacy of PDT was the EVER-EST study, 11 in which 61 patients with PCV were randomized into one of three treatment arms: verteporfin PDT combined with intravitreal ranibizumab (Lucentis; Genetech, South San Francisco, CA), PDT with sham injection, or intravitreal ranibizumab with sham PDT. At the primary endpoint of the study (6 months), complete polyp regression was observed in 77.8% of patients in the group receiving PDT and ranibizumab and 71.4% of the group receiving PDT monotherapy, compared to only 28.6% in the ranibizumab monotherapy group. The group receiving combination therapy experienced a larger gain in VA and greater reduction in retinal thickness compared to the ranibizumab monotherapy group, although the differences were not statistically significant.
Due to the relatively small sample size, the EVEREST study was not powered to detect a difference in VA or retinal thickness among the treatment arms. This, together with the short study duration (6 months), were limitations of this study and formed the impetus for a larger subsequent study.
The EVEREST II study 12 was a 24-month, multicenter, randomized, double-masked study that compared the efficacy of PDT combined with ranibizumab against ranibizumab and sham PDT among patients with symptomatic macular PCV. From 42 sites in Asia, 322 patients with PCV were Practical Retina randomized equally into each of the two study arms. In both EVEREST and EVER-EST II, the diagnosis of PCV was confirmed by a Central Reading Center (Fundus Image Reading Center, National Healthcare Group Eye Institute, Singapore) using standardized diagnostic criteria. 9 Patients were treated with three loading doses of ranibizumab monthly, followed by additional ranibizumab injections pro re nata (PRN) based on prespecified retreatment criteria. Patients in the combination arm received verteporfin PDT at the start and PRN at three monthly intervals if polyps were detected on ICGA, whereas those in the monotherapy group received sham PDT.
At month 12, patients in the combination arm gained 8.3 letters, compared to 5.1 for the monotherapy arm (P = .01), and 24.5% gained 15 letters or more compared to 14.0% in the monotherapy arm (P = .03). Complete polyp regression was significantly higher in the combination arm, and almost double that of the monotherapy arm (69.3% vs. 34.7%; P < .001). The mean reduction in central subfield retinal thickness was greater in the combination arm (least squares mean, -164.9 µm vs. -113.4 µm; P < .001). Correspondingly, the percentage of patients with disease activity at month 11 was 20.5% in the combination arm compared to 50.0% in the monotherapy arm.
In addition to better treatment efficacy, patients treated with combination PDT and ranibizumab also required fewer injections. The Practical Retina median number of ranibizumab injections was four compared to seven for the monotherapy arm. Overall, 61.0% of patients in the combination arm only required one PDT treatment (at baseline) during the 12-month period. Despite the proven efficacy of PDT combined with anti-VEGF agents, some clinicians have debated whether all patients with PCV require PDT. To attempt to address this, randomized clinical trials have been conducted on deferred PDT, or rescue PDT.
The FUJISAN study 18 was a prospective, randomized clinical trial where patients received ranibizumab with either PDT at baseline or deferred PDT (at 3 months). Both groups experienced similar gains in VA (8.1 letters vs. 8.8, respectively), whereas the reduction in retinal thickness was greater among the group receiving initial PDT (-184.5 µm vs. -145.6 µm). In this study, the mean number of ranibizumab injections during the 12-month period was 4.5 and 6.8, respectively.
The PLANET study 19 was a randomized, doubleblind study where 310 patients diagnosed with PCV received three initial monthly doses of aflibercept (Eylea; Regeneron, Tarrytown, NY). At week 12, all patients were randomized into two arms: the first received aflibercept every 4 weeks with active PDT only if specific treatment criteria were met (termed "rescue PDT"), whereas the other group received aflibercept every 4 weeks and sham rescue PDT.
At month 12, VA gains were similar in both groups (10.8 vs. 10.7 letters), as were the reduction in CSFT (-143.5 µm vs. -137.7 µm). The percentage of patients with complete polyp regression at week 52 was 44.8% for the active rescue PDT group and 38.9% for the sham rescue PDT group. Of note, fewer than 15% of patients in either group required rescue PDT treatment, based on the study treatment protocol.
PROSPECTIVE, MULTICENTER CLINICAL TRIALS ON PCV TREATED WITH ANTI-VEGF MONOTHERAPY (TABLE 2)
Although PDT has been shown to be effective in treating PCV, some ophthalmologists believe that PCV can be effectively treated using anti-VEGF monotherapy. In addition to outcomes of the anti-VEGF monotherapy arms of the randomized controlled trials discussed above, evidence for the efficacy of anti-VEGF monotherapy can be obtained from several prospective, multicenter, noncomparative, single-arm studies where PCV patients were treated using anti-VEGF agents alone.
The APOLLO study 6 was an open-label, prospective, multicenter, single-arm clinical trial of 50 patients with PCV treated with intravitreal aflibercept monthly for 3 months, then every 2 months (at months 4, 6, 8, 10, and 12) . After 12 months, mean gain in VA was 10.5 letters, with 72.5% of patients reported to have complete polyp regression. The mean central subfield thickness decreased from 355.7 µm at baseline to 238.5 µm at 12 months (P < .0001).
Similarly, the VAULT study 20 treated 40 patients with PCV with intravitreal aflibercept monthly for 3 months, then every 2 months thereafter. At month 12, the mean gain in VA was 9.0 letters, and 66.7% of patients were reported to have complete polyp regression. Mean subfield macular thickness de- 21 was a 24-month, phase 4, randomized, double-masked, controlled, multicenter study that examined the treatment outcomes of ranibizumab monthly for the first 12 months compared to ranibizumab PRN. After month 12, patients in both treatment arms were treated with ranibizumab PRN. Among the cohort of 333 patients, 139 (41.7%) were diagnosed by the reading center to have PCV. Of these, the mean gain in VA at month 24 was 12.3 letters for the group treated initially with monthly therapy and 9.7 for the group treated with PRN.
CONCLUSION
The 1-year results from two large, prospective, multicenter clinical trials, EVEREST II and PLANET, provide important information that influences the paradigm of PCV management. It has been shown that combining PDT with an anti-VEGF agent increases the rate of complete polyp regression and reduces the treatment burden. The optimal time to perform PDT (whether at the initial treatment or in a deferred or rescue mode) remains the subject of discussion. Additional considerations for future studies will include identifying which patients will benefit from early PDT and those in which PDT may safely be deferred. On the other hand, treatment with anti-VEGF monotherapy has been shown to result in improvements in VA and reduction in central macular thickness, although its efficacy in terms of complete polyp closure is variable.
